Please assess the completion status of the following clinical trial:

Trial Title: Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years or older.~* Diagnosis of low or Int-1 risk MDS~* Low platelet count, and/or low hemoglobin, and/or RBC transfusion-dependent and/or platelet transfusion-dependent~* ECOG Performance status 0-2~* Standard safety inclusion for serum creatinine, AST, ALT, bilirubin.~* Serum bicarbonate greater than or equal to 20 mEq/L.~* Use of acceptable birth control.~* Signed, written informed consent.~Exclusion Criteria:~* Diagnosis of acute PML.~* Previous or concurrent malignancy.~* Prior treatment with azacitidine or other demethylating agents.~* Treatment with any anticancer therapy or investigational drugs within 21 days.~* Hypersensitivity to azacitidine or mannitol.~* Presence of GI disease.~* Active, uncontrolled infection.~* Known Human Immunodeficiency Virus (HIV) or Hepatitis C, or known active viral Hepatitis B.~* Breastfeeding or Pregnant females;~* Presence of serious illness, medical condition, or other medical history which would be likely to interfere with a subject's participation in the study or with the interpretation of the results.~* Current congestive heart failure (NY Heart Association Class III-IV), unstable angina or angina requiring surgical or medical intervention within 6 months, myocardial infarct within 6 months, or uncontrolled cardiac arrhythmia.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Subcutaneous (SC) Azacitidine and Oral Azacitidine (Type: EXPERIMENTAL): Cycle 1 subjects receive SC Azacitidine for first 7 days of 28 day cycle. For Cycle 2 and beyond subjects receive Oral Azacitidine (experimental) for first 7 days of 28 day cycle.
- Oral Azacitidine (Type: EXPERIMENTAL): Subjects receive Oral Azacitidine (experimental) QD or BID for the first 14 or 21 days of 28 day cycle.

Based on this trial design, predict the completion outcome and termination type (if applicable).